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 Spinal muscular atrophy with lower extremity predominance (SMA-LED) is an 
autosomal dominant congenital form of motor neuron disease. The most common cause of 
SMA-LED are mutations in dynein cytoplasmic 1 heavy chain 1 (DYNC1H1), which 
encodes the largest subunit of the retrograde motor cytoplasmic dynein 1.  As is typical in 
other cases of SMA-LED, patients harbouring the DYNC1H1 p.R399G mutation exhibit 
lower limb weakness as a consequence of muscle atrophy and also show a degree of 
cognitive impairment. However, the underlying molecular pathogenesis remains unknown. 
In addition to its characteristic function in retrograde trafficking, the dynein complex is 
increasingly understood to be involved in other cellular processes including growth cone 
dynamics and regulation of the Golgi apparatus. Here, we show that fibroblasts with the 
DYN1C1H1 p.R399G mutation exhibit a striking loss of Golgi apparatus integrity as 
measured by increased fragmentation, which correlates with increasing zygosity of the 
mutation. Importantly, we also see a decrease in the localisation of the dynein complex to 
the Golgi cisternae and a significant decrease in the acetylation of microtubules in the peri-
nuclear region. Excitingly, the treatment of mutant fibroblasts with tubacin, an HDAC6 
inhibitor, caused a striking amelioration of the Golgi apparatus integrity by increasing 
microtubule acetylation. This highlights for the first time a perturbed dynein-mediated 
regulation of microtubule acetylation and the fragmentation of the Golgi apparatus as a 
contributory factors in the pathogenesis of SMA-LED. Importantly, these data also illustrate 
that ameliorating the microtubule acetylation is sufficient to rescue the Golgi integrity, 
thereby providing a potential therapeutic target for this pathology.   
